1. Subjects whose consent is obtained in writing prior to the clinical trial from a
guardian after a full explanation. For subjects over 7 years old, it is desirable that
an informed assent is also obtained from the pediatric subject him/herself when
possible.
2. Subjects aged ≥45 weeks CGA to of subject.
3. [Elective surgical cases] Subjects classified as American Society of Anesthesiologists
(ASA) (ASA physical status classification) Class I to III by preoperative diagnosis.
4. [Elective surgical cases] Subjects who require at least 6 hours of respiratory
management with intubation under intensive care from immediately after surgery and are
anticipated to require sedation.
5. [Medical ICU cases] Subjects who require at least 24 hours of respiratory management
with intubation under intensive care and are anticipated to require sedation. For
medical ICU cases, sedatives used prior to treatment with the investigational product
should be discontinued before the start of treatment with the investigational product.
6. If a subject is a female of childbearing potential, she should not be pregnant or
possibly pregnant, or lactating.
1. Subjects who are judged by investigator or sub-investigator to have a neurological
disease that will make sedation assessment difficult, such as:
- Subjects with brain damage which is expected to increase intracranial pressure
due to trauma or central nervous system disease
- Subjects with cerebral palsy, autism, severe mental retardation, etc.
- Subjects with paralysis due to continuous administration of a muscle relaxant or
due to a spinal injury of class T5 or higher.
2. Subjects with 2nd or 3rd degree heart block during the tests at the screening visit
(excluding subjects using a pacemaker).
3. Subjects with any of the following low blood pressure levels during the tests at the
screening visit:
- Age ? 45 weeks CGA to
- Age ? 1 year old to
- Age ? 10 years old to
4. Subject of bradycardia (?10th centile of heart rate for healthy children) during the
physical examination at screening period.
5. Subjects with ALT ?100 U/L during the laboratory tests at the screening visit.
6. Subjects in whom dexmedetomidine or other alfa 2 receptor agonists, alfa 2 receptor
antagonists and drug that may be used in this study are contraindicated.
7. Subjects who may need a sedative or analgesic (including narcotics) other than
dexmedetomidine, midazolam or fentanyl during treatment with the investigational
product.
8. Subjects who have acute febrile illness [with a temperature (core or tympanic) ?
38.0°Centigrade] at the screening visit.
9. Subjects who received other investigational product within 30 days before baseline or
subjects who will participate in other study that uses an investigational product
during the study period.
10. Subjects who received dexmedetomidine within 48 hours before baseline.
11. Subjects who, in the opinion of the investigator or sub-investigator, may be at
increased risk to the subject due to the conduct of the study or may have a disease or
factor which will probably preclude the obtainment of sufficient study data.
12. Subjects for whom, in the opinion of the investigator or sub-investigator, risks
involved with administration of dexmedetomidine outweigh its benefits (e.g., >2 doses
of vasopressor due to cardiogenic shock).
13. Subjects who are investigational site staff members directly involved in the conduct
of the study and their family members, site staff members otherwise supervised by the
investigator, or subjects who are Sponsor's employees directly involved in the conduct
of the study.